Corcept Therapeutics Incorporated (LON:0I3Q)

Market Cap	3.15B -38.4%
Revenue (ttm)	551.39M +17.9%
Net Income	77.86M -25.2%
EPS	0.65 -30.7%
Shares Out	n/a
PE Ratio	40.43
Forward PE	69.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30
Average Volume	5,078
Open	40.75
Previous Close	39.78
Day's Range	39.65 - 41.00
52-Week Range	33.00 - 115.27
Beta	0.23
RSI	37.01
Earnings Date	Feb 18, 2026

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 500
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0I3Q

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD